President Donald Trump has recently reached out to pharmaceutical companies in a letter, urging them to reduce drug prices, as outlined in an executive order signed in May. However, experts note that Trump’s capacity to compel these companies to lower their prices is limited, as his approach effectively constitutes price control.
This strategy of applying public pressure might be a tactic Trump uses to encourage compliance from businesses, according to Benedic Ippolito, a senior fellow at the conservative American Enterprise Institute. He commented that the substantial question is whether the administration can realistically motivate drug manufacturers to take even minor voluntary steps.
There’s a visible public discourse surrounding Trump’s directive aimed at reducing drug prices. The current trend shows a stark increase in these prices; the Department of Health and Human Services reported that prescription drug prices surged by over 15% from January 2022 to January 2023, averaging around $590 per drug, with nearly half of the 4,200 listed drugs experiencing price hikes that outpaced inflation.
Trump’s original executive order mandates the Department of Health and Human Services to set price targets for pharmaceutical manufacturers. Failure to comply may lead the Department of Justice and the Federal Trade Commission to consider enforcement actions against anti-competitive practices, among other repercussions. Furthermore, Trump proposed initiating “drug pricing in the most favorable countries,” emphasizing that Americans should pay the same prices as those in other developed nations.
Yet, Ippolito suggests that any real reduction in drug prices hinges on the administration’s ability to apply pressure on pharmaceutical companies effectively. He pointed out the limited leverage the administration has, noting that Congress holds greater authority to enact laws that significantly impact the drug market. In reality, there appears to be little alignment on this issue within Trump’s own party.
Michael Cannon from the Cato Institute remarked that the executive order effectively represents government-imposed price control, which raises concerns as it doesn’t have Congressional backing. Price controlling, he explains, entails government intervention to dictate how much can be charged in the free market. While it could potentially lower costs for some consumers, historical examples, like Nixon’s price controls in the 1970s, show limited success.
Cannon added that there are various alternative pathways to achieve reduced drug prices, involving reforms in Medicaid, Medicare, and tax laws, but these would necessitate Congressional involvement. He expressed skepticism about passing any measures through Congress aimed at cutting inefficiencies in healthcare spending.
In the meantime, the White House’s recent letter was sent to several drug companies, including AbbVie, Amgen, and Johnson & Johnson, advocating for lower drug prices.
